Podcasts about Oncology

The ‘CHATGPT' Of Oncology: How AI Is Bridging The Gap In Cancer Care A person's life expectancy should never be determined by their zip code, yet access to top-tier cancer centers remains a major factor in survival rates. To bridge this gap, a new AI-driven platform is providing patients with expert breakdowns of their specific diagnosis. Our experts this week discuss how this new tool is ensuring all patients have access to the most effective and up-to-date care strategies available. Guest: Simone Jensen, founder & CEO, Radical Health; Elisabeth Drabkin, board member, Radical Health's Patient Advisory Board Host: Elizabeth Westfield Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

"The disease is increasingly managed as a chronic condition rather than a diagnosis with an immediate terminal outcome. Particularly, with earlier and more effective and sustained treatment options, we can make this disease a very chronic, long-term, livable condition. I want to make sure that patients are aware that this is not a death sentence. This is something that patients can live with for the long term," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about long-term multiple myeloma considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 6, 2027. Ann McNeill is on the speakers' bureau for Pfizer. This financial relationship has been mitigated. All other planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to management of long-term side effects related to multiple myeloma and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 201: Which Survivorship Care Model Is Right for Your Patient? ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments Infection Prevention for Oncology Nurses Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Survivorship Programs Sexual Considerations for Patients With Cancer Oncology Nursing Forum articles:  A Qualitative Study of the Experiences of Living With Multiple Myeloma Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Huddle Cards: Pain Management Sexuality Survivorship Care Plan ONS Learning Libraries: Hematology, Cellular Therapy, and Stem Cell Transplantation Survivorship ONS Symptom Intervention resources: Chronic Pain Fatigue Peripheral Neuropathy American Cancer Society: Living as a Multiple Myeloma Survivor Blood Cancer United: Resources for Healthcare Professionals International Myeloma Foundation: Resources and Support for the Myeloma Community Multiple Myeloma Research Foundation: Empower Patients and the Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We do consider myeloma an incurable hematologic malignancy, even though we have had improvements in survival. But just like for any malignancy, our goal is to maximize survival. We want to eliminate as many myeloma cells as we possibly can. And subsequently, we want to improve the quality of life for these patients in the long term. So those are basically our treatment goals. That's what we think of when we're treating patients all throughout their treatment journey." TS 1:39 "It is very typical for patients along their journey to have received several lines of therapy. I think it's important to realize that the cells acquire new mutations, making them more resistant to these further subsequent lines of therapy. We see quicker, more aggressive relapses in those patients with multiple prior lines of therapy. We can see an increase in the CRAB symptoms, which are the calcium elevations, the renal dysfunction, profound anemia, and even bone disease. We can see a rapid rise in the monoclonal protein in the labs or even a very rapid rise in the involved light chain in that serum free light chain assay, so it's important to monitor these labs." TS 9:14 "All oncology nurses are focusing on these survivorship plans now. And I think that's a great thing when you think about a diagnosis of cancer and a survivorship plan, because it means these patients are living a longer time. We still look at long-term health maintenance guidelines depending on the patient's sex and their age. ... I think preventing infection is always going to be something absolutely on the forefront in our survivorship plan with myeloma. I mean, myeloma is an immune system malignancy. The treatments that we have given patients can sometimes, especially in later life therapies, further compromise the immune system. So, we're always looking to prevent serious infection." TS 12:46 "Patients get treatment, especially induction therapy. They may or may not get transplant. They may have been on a very minor maintenance schedule, depending on their age. And they feel really well. And then they decide not to return for their follow-up because they feel so good. I think nurses are critical in the communication aspect of the patient-provider aspect. So, nurses are really the key means of communication. The providers are absolutely important—the physicians, the nurse practitioners and every other member of the team—but I think the nurses have a really special rapport with patients. They're usually the ones providing the education on the treatment regimens. They're managing the toxicity profiles. They're doing all the coordination of care between visits. They are really going to be the ones telling the patient, 'Hey, you're going to feel good and that's a wonderful thing, but you still need to come once a month or once every six weeks or once every two months for your labs.'" TS 15:17  "It has been amazing. The science, the research, the treatments, the approvals from the U.S. Food and Drug Administration. Survivorship has improved dramatically. Let's take the first few years of the new century, right? The five-year survival rate was about 38%. If you then jump to 2015–2019, which is still seven plus years ago, it has doubled. So, we're talking about anywhere from 60%–80% over a five-year survival. So that's an amazing improvement in their five-year survival rate for myeloma." TS 23:28 "Survivorship in myeloma begins at diagnosis, not just after treatment. And I think that because it is managed as a chronic, often relapsing disease, it does require lifelong evolving care. Patients should realize that they will know us for the rest of their lives. We will know everything about you. I always tell them, 'I will know everything about your hobbies, your children, your grandchildren, what you love to do on the weekends.' It's very important that that point is made right at diagnosis, not just after so many lines of treatment. It's very important that we are going to follow these patients throughout their journey." TS 28:18

In this insightful interview, Dr. Desiree Feierabend shares her journey into oncology rehabilitation, emphasizing the importance of early prehab, manual therapy, and emotional support for cancer patients. Discover practical strategies for integrating rehab into cancer care and supporting patients through their challenging journeys. Key Topics Oncology rehabilitation journey Importance of prehabilitation in cancer care Manual therapy and pelvic health in oncology Addressing emotional and mental health in cancer patients Integrating rehab with medical teams for holistic care

Featuring an interview with Dr Christopher Lieu, including the following topics: Historical approach to the adjuvant treatment of localized colorectal cancer (CRC) (0:00) Perspectives on earlier-onset colorectal cancer and potential drivers; management of oligometastatic disease (13:16) Overview of cell-free DNA (circulating tumor DNA [ctDNA]) and techniques for its measurement (17:03) Reliability and prognostic capability of ctDNA as a biomarker for clinical status in patients with localized colorectal cancer (21:10) ctDNA assessment and treatment decision-making for patients with Stage II colon cancer (26:38) Potential incorporation of ctDNA assays into the management of metastatic colorectal cancer or microsatellite instability-high disease (34:29) Available clinical data with ctDNA assessment in localized rectal cancer (38:54) Current practice patterns with ctDNA assays for patients with localized colorectal cancer (41:17) Case: A woman in her early 40s with resected lower risk Stage III colon cancer requests ctDNA testing (45:47) Case: A man in his early 50s with Stage IIIB colon cancer wants to avoid adjuvant chemotherapy (50:39) Case: A man in his early 60s with Stage IV colon cancer receives a positive postoperative ctDNA assessment result (53:24) NCPD information and select publications

Send a textDr. Tomasz Beer, MD is a nationally recognized medical oncologist and clinical research leader who serves as Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation ( https://www.exactsciences.com/ ), a molecular diagnostics company focused on the eradication of cancer by preventing it, detecting it earlier, and guiding personalized treatment.Before joining Exact Sciences, Dr. Beer spent decades at the forefront of academic oncology, including serving as Deputy Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, where he helped build one of the country's leading precision cancer programs.A prostate cancer specialist by training, Dr. Beer has led numerous clinical trials, authored hundreds of peer-reviewed publications, and been a driving force in advancing biomarker-guided cancer therapy. His career has spanned the evolution of oncology—from empiric chemotherapy to precision medicine and now toward population-scale cancer detection.Today, Dr. Beer is helping lead one of the most ambitious shifts in cancer care: moving from late-stage treatment to early detection across multiple tumor types through advanced molecular diagnostics and blood-based screening technologies.#MultiCancerEarlyDetection #CancerInterception #LiquidBiopsy #PrecisionOncology #CancerPrevention #Immunotherapy #EarlyDetection #OncologyInnovation #CancerResearch #MCEDSupport the show

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The BBC has had exclusive access to the world's largest study scanning pregnant women's brains. The BeMOther project is based in Spain and has found that women's brains change significantly through pregnancy and beyond. We learn more about the changes and ask why Matrescence - and the transformations that can come with pregnancy, birth and raising a child - are only just starting to receive attention as a distinct life-stage. There's even a campaign to get the word in US dictionaries. Nuala McGovern talks to Smitha Mundasad, a BBC health and science reporter who visited the trial in Spain for her documentary, Baby Brain: What's Really Going On? and Lucy Jones, the journalist and author of Matrescence: On the Metamorphosis of Pregnancy, Childbirth and Motherhood. Hester Musson's latest book is The Night Hag. It's a Victorian Gothic novel which takes place in 19th century Scotland. It delves into themes including the budding science of archaeology, spiritualism and folklore legends, but at its heart is the question of the role of women in Victorian society. A major global study says more than a quarter of healthy years lost to breast cancer could be prevented through lifestyle changes like cutting red meat, staying active and not smoking. The Lancet Oncology analysis shows cases worldwide are set to rise by a third, reaching over 3.5 million by 2050. We are joined by Professor Jayant Vaidya, Professor of Surgery and Oncology at University College Hospital, London, Dr Liz O'Riordan, a former breast cancer surgeon who herself has had breast cancer and is currently in remission, and Claire Rowney, Breast Cancer Now's chief executive, who has been recently diagnosed with breast cancer. Last week, news broke of the killing of one of Mexico's most dangerous men - known as El Mencho. He was killed by the Mexican military. He ran one of Mexico's most powerful drug cartels, the Jalisco Cartel New Generation. In response, members of his cartel torched businesses and buses across the country. But among the burnt-out cars, a new wave of posters appeared, with the faces and names of some of Mexico's 130,000 people who are either missing or disappeared – a tactic used by criminal cartels. The people taping their faces to walls are often their mothers, part of groups fighting to find out what happened to their loved ones. They are known as 'madres buscadoras' or searching mothers. Journalist Andalusia Soloff joins us from Mexico City, she has been following stories like these for years.Presenter: Nuala McGovern Producer: Helen Fitzhenry

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Drs. Isaacs and Traina discuss new data in HER2+ breast cancer from the 2025 San Antonio Breast Cancer Symposium, focusing on early-stage studies including DESTINY-Breast11 and DESTINY-Breast05 and how data from these studies could potentially impact patient care in the future.

EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about Vortex Biotech's advancement in liquid biopsy technology and how the company fits within its "venture building" strategy. Iliev explained that Vortex addresses a significant public healthcare need in early cancer diagnostics, particularly as the industry shifts away from traditional tissue biopsies toward liquid biopsy approaches. He highlighted that tissue biopsies are often painful, costly, and limited in frequency, whereas liquid biopsies offer a less invasive and more scalable alternative. Vortex managing director Paul Reeves described how the Vortex platform supports precision medicine by delivering precise and comprehensive tumour biology information. Unlike antibody- or magnet-based systems, the Vortex platform uses a purely physics-based microfluidics approach to isolate circulating tumour cells (CTCs), avoiding selection bias and preserving cell integrity. Reeves said: “We are uniquely gentle on the cell… you can turn one circulating tumour cell into a million cells.” This capability enables potential applications in drug discovery and drug testing, opening additional market opportunities beyond early diagnostics. The company has also been selected for AstraZeneca's expanded exchange program, providing validation of its science and strategy, alongside partnerships including Europe's largest private pathology laboratory. Vortex Biotech is currently midway through global clinical validation studies and is progressing toward regulatory submissions and broader UK and European commercial rollout. For more interviews like this, visit Proactive's YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don't miss future content. #EMVCapital #VortexBiotech #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine #CirculatingTumorCells #OncologyInnovation #Microfluidics #DrugDiscovery #ClinicalValidation #HealthcareInnovation #BiotechInvesting

Everyone is at risk of breast cancer. Some are more at risk than others due to hereditary factors – such as a family history of cancers – and lifestyle choices that affect our overall health. Knowing your risk of breast cancer can help you decide what steps to take to lower your risk. Joining me today is Dr. Jennifer Ligibel, a Susan G. Komen Scholar and Komen grantee, Professor of Medicine at Harvard Medical School, Senior Physician at the Dana-Farber Cancer Institute and an expert on the impact of lifestyle factors, cancer risk and outcomes. Through more than a dozen lifestyle intervention trials, Dr. Ligibel has evaluated the impact of exercise, weight loss, fitness, body composition and quality of life in cancer patients and survivors.

How do you go from fashion merchandising to the "cream of the crop" in Oncology sales? Marilu Restrepo, an Executive Sales Specialist in Hematology/Oncology, shares her raw, personal journey—from a Division I athlete to losing her cousin to breast cancer—and how that tragedy transformed into a high-stakes career helping cancer patients.Marilu's insights on "Selling with Passion," leveraging AI for pre-call planning, and overcoming rejection are essential listening.TOPICS:* Selling with Passion: Why your "Why" helps you overcome any clinical objection.* The Inside Sales Foundation: Developing the confidence to handle high-volume rejection.* The Oncology Shift: How to manage complex territories and collaborate with clinical teams.* AI Productivity: How Marilu uses ChatGPT to brainstorm probing questions and stay organized.CHAPTERS:00:00 – Meet Marilu Restrepo: From D1 Track to Executive Sales.02:15 – The Turning Point: How a family tragedy changed her career path.04:30 – Inside Sales 101: Why the "grind on the phone" is a lost art.06:55 – Overcoming Rejection: Applying to 40+ jobs and winning.09:20 – The "Fire" of the OR: Navigating high-intensity Cardiac Device sales.12:10 – Making the Leap: Breaking into Oncology and Prostate Cancer.15:00 – Working with the Team: Collaborating with MSLs and Nurse Educators.17:45 – The Modern Rep: Using AI & ChatGPT for elite pre-call planning.20:15 – Life Outside the Lab: Balance, Motherhood, and... the best Italian in Ohio?23:10 – Final Advice: Why your "Why" is your greatest sales tool.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlighted the need for oncologists to recognize and address depression for patients with cancer. In a new episode of Oncology on the Go created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, spoke with Boris Kiselev, MD. Together, they explored the complex intersection of oncology and psychiatry. The conversation challenged the oversimplification of “cancer-related sadness” to provide clinicians with a framework for distinguishing between normative grief and clinical Major Depressive Disorder (MDD).The conversation focused on: The Diagnostic Continuum: Depression exists on a spectrum ranging from normative sadness—encompassing a healthy, waxing-and-waning response to trauma—to pathological MDD. Differentiating Grief vs Depression:  Grief/Normative Sadness: Often occurs in waves, improves over time, and does not typically affect a patient's functional ability. It is often a response to the loss of one's “pre-cancer self”.   Clinical Depression: Marked by anhedonia (loss of pleasure), persistent feelings of guilt or worthlessness, and a fundamental change in identity where the patient no longer “feels like themselves”.   The “Quantum” Observation Effect: Patients often present differently to oncologists than they do to mental health professionals. In the oncology clinic, patients may unconsciously “shield” their distress to ensure that their treatment plan remains unchanged. The Power of the Story: The experts emphasized that the oncologist-patient relationship is therapeutic. Allowing patients to “tell their story” rather than jumping straight to clinical data builds trust with them and uncovers hidden psychological pressure points. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor in the Psycho-oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in Internal Medicine.

This week, we explore early colorectal cancer. Maybe it's just this week, but there were plenty of “IDEAS” around. Michael highlights the importance of choosing an appropriate adjuvant regimen, whether that be FOLFOX or CAPOX. Josh digs a bit deeper and, as the name suggests, looks at whether patients with liver metastases can be cured with chemotherapy and a liver transplant.Studies discussed in this episode:IDEASTransMETEORTCFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

"We print education sheets that we have, and we say, 'Just ignore this part that says cancer. You're getting this med but for a different indication.' And then you have to really point out what our goals of care are. You're using the information that, as oncology nurses, we like and love, but we're having to cross it out and say, 'Just read this portion and just do this here.' And that can be challenging for the nurse and probably confusing for the patient," ONS member Brandy Thornberry, RN, OCN®, outpatient infusion and VAD supervisor at Logan Health in Kalispell, MT, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about education for patients receiving antineoplastic drugs for non-oncology indications. Taylor also spoke with ONS members Lizzy McMahon, BSN, RN, OCN®, and Jennifer Lynch, BSN, RN, TCTCN™, about general antineoplastic treatment education and tailoring education in the stem cell transplantation setting. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 27, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge of best practices for educating patients receiving antineoplastic therapies across oncology, non‑oncology, and stem cell transplant settings. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 259: Patient Education for Health Literacy and Limited English Proficiency Episode 197: Patient Learning Needs and Educational Assessments Episode 183: How Oncology Nurses Find and Use Credible Patient Education Resources Episode 179: Learn How to Educate Patients During Immunotherapy Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease ONS Voice articles: Online Tool Helps You Apply Health Literacy Principles to Written Patient Education Personalized Patient Education: Ensure Effective, Inclusive, and Equitable Patient Education With These Five Strategies Policies and Procedures for Written Patient-Facing Cancer Education Materials Oncology Nursing Forum article: An Integrative Review of Patient Education During Inpatient Hematopoietic Stem Cell Transplantation ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library Patient Education Sheets: Cancer Care, Explained To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode McMahon: "A great question would be to ask the patient what they already know and what they're most concerned about or what their biggest questions are. This way, the nurse can tailor their education to make sure to focus on what the patient doesn't know yet and what they're most concerned about, while still touching on all the required education topics. … It's also important for nurses to continually be assessing the patient's readiness to learn throughout the education session, looking for nonverbal cues or verbal signs that the patient is overwhelmed or anxious because this is going to interfere with their ability to take in new information." TS 3:49 Thornberry: "A lot of the education sheets and the products for them explain it like, 'This is cancer,' and more of an oncology perspective, so occasionally [non-oncology patients] can show up and be confused by it. I do feel like they come a little bit less prepared than our oncology patients. Our rheumatologists and neurologists, they sure try, but they just don't have the support in that realm either. They're full of every question you can imagine. They've never been to an infusion room. They don't know what to bring. Can they drink water and have their meds beforehand? It's a full gamut of really preparing them to get these for autoimmune or rheumatology-type issues." TS 14:12 Lynch: "I really want to spend time with those patients to make sure that we are not assuming that they are coming to us with any knowledge or experience. I want them to be able to come to us with questions and trust their healthcare team and really sit down with them and say, 'Okay, you don't have cancer, but we're using the word chemotherapy where we're talking about cancer drugs.'… And we're going to probably spend more time going over some of the basics about blood stem cells, types of cells that they grow into, how your body fights infection, what they're going to be at risk for. The side effects can be pretty scary when you're talking about them, especially back to back. So making sure that we are delivering the information that doesn't put them in a panic mode… A lot of reassurance, as well, and just taking into consideration that, yes, this might have this whole other layer of anxiety to it because of the unknown." TS 32:22

This episode explores an exciting new way the immune system can be supported using tiny messengers released by natural killer immune cells. These messengers help the body's built-in defense system better spot and remove harmful or worn-out "zombie" cells that drive inflammation and speed up aging. The core idea is simple: help the immune system do its job more effectively, without harming healthy cells. It's cutting-edge science explained in plain language, with big implications for long-term health and resilience.   Key Takeaways To Tune In For: (06:31) – NK Cell Exosomes: Tumor Agnostic Action (12:18) – Risks and Personalized Treatment (17:21) – Integrative Cancer Care and Oncology (21:13) – Patient Selection and Exosome Scarcity (24:44) – Enhancing Treatment: Diet, Hormesis, and Supplements (29:28) – Ongoing Care and Future Applications   Resources talked about in this episode: Websites: https://recellebrate.com/   Social media handles: IG TikTok YouTube LinkedIn  

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show

Bhavana (Tina) Bhatnagar, DO—Associate Professor of Medicine at the WVU Cancer Institute—shares her journey from academic centers to rural West Virginia, where she's working to expand access and improve outcomes for underserved communities. We talk about what high-quality rural cancer care really takes: overcoming transportation and financial barriers, navigating limited specialty resources, building community-based clinical trials, and expanding access to innovations like CAR T—powered by strong multidisciplinary teams.Key takeaway: the best care starts with understanding the person behind the patient.

This review series focuses on recent advances in resolving macro and molecular structures that have driven the field of occlusive thrombus structure and function forward. Covering multiple contributions to thrombosis, eg, platelets, factor XIII, and the contact system, the series also looks to put this new knowledge into the context of future advances in diagnostic and therapeutic tools to enhance normal hemostasis while preventing and treating unwanted thrombosis. Blood Associate Editor, Dr. Thomas Ortel discusses this series with Drs. Alisa Wolberg, Jonas Emsley, and John Weisel, who all contributed to articles in the Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions which can be found in volume 146, issue 12 of Blood. 

Bruce Chabner is a professor of medicine at Harvard Medical School and clinical director emeritus of the Massachusetts General Hospital Cancer Center. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. I.D. Goldman and B.A. Chabner. Cerebral Folate Deficiency, Autism, and the Role of Leucovorin. N Engl J Med 2026;394:833-835.

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, sat down with OncLive to discuss treatment goals and other patient factors weighed when navigating first-line chemotherapy selection in metastatic pancreatic cancer.Shroff is the associate director of clinical investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Comprehensive Cancer Center in Tucson. She also is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology for the University of Arizona College of Medicine – Tucson, and medical director for the Oncology Service Line with Banner Health. Spencer is a medical oncologist and director of the Phase 1 Program at the New York University Langone Perlmutter Cancer Center.In the exclusive interview, Drs Shroff and Spencer discuss the evolving role of NALIRIFOX within the frontline treatment paradigm; the decision between standard first-line chemotherapy and clinical trial enrollment for patients with metastatic pancreatic cancer; and the importance of mentorship and leadership development for women in the field of gastrointestinal oncology._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send a textThe final weeks before the ABPTS Oncology Exam can feel emotionally intense, even when preparation has been solid. Anxiety often increases, and it's tempting to change everything at the last minute.In this episode, we talk about how to approach the final stretch with focus and restraint, why last-minute overhauls increase stress, and how confidence comes from execution — not cramming.In this episode, we cover:• Why anxiety spikes close to exam day• How last-minute overcorrections undermine confidence• The role of containment and focus• What finishing well actually looks likeLooking for more structure and clarity?You can watch the full YouTube playlist that supports this stage of exam prep here:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7 Looking for more structure and clarity?If you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure what to focus on, I've created a short YouTube playlist designed to help you study with more clarity and confidence.These videos walk through prioritization, common pitfalls, and how to think about exam prep more strategically — without Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Listen to JCO's Art of Oncology article, "Mother's Grief" by Dr. Margaret Cupit-Link, who is an assistant professor of pediatric hematology/oncology at Cardinal Glennon Children's Hospital of St. Louis University. The article is followed by an interview with Cupit-Link and host Dr. Mikkael Sekeres. Dr Cupit-Link shares a pediatric oncologist's experience of a patient's death through the new lens of motherhood. TRANSCRIPT AOO 26E03 Narrator: Mother's Grief, by Margaret Cupit-Link, MD, MSCI  Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm professor of medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a treat it is today to have joining us our third place Narrative Medicine Contest winner, Maggie Cupit-Link, an assistant professor of Pediatric Hematology Oncology at Cardinal Glennon Children's Hospital of St. Louis University to discuss her Journal of Clinical Oncology article, "Mother's Grief." Both Maggie and I have agreed to call each other by first names. Maggie, thank you for contributing to the Journal of Clinical Oncology and for joining us to discuss your winning article. Maggie Cupit-Link: Thank you so much for having me and for choosing my article. It's an honor to get to speak with this group. I know a lot of our listeners have a lot in common with us in our profession, so I'm excited to be here. Mikkael Sekeres: We're excited to have you. You are such a terrific writer. Tell us about yourself. Where are you from, and walk us through where you are at this stage of your career? Maggie Cupit-Link: I grew up in a small town in Mississippi called Brookhaven, and I ended up attending college in Memphis, Tennessee, which is important to note because I was a pre-med student when I got diagnosed with childhood cancer, Ewing sarcoma, at the age of 19. And so that really shaped my career goals. And I was treated at St. Jude Children's Research Hospital, which is very formative as well, given that I was surrounded by childhood cancer patients. I ended up doing my medical school at the Mayo Clinic Medical School in Minnesota, which was very cold for me but a wonderful experience. And then went to St. Louis to WashU, St. Louis Children's for my residency, and then back to Memphis for my fellowship at St. Jude. But now I'm back in St. Louis at the other hospital, Cardinal Glennon, which is affiliated with St. Louis University. And my husband's originally from St. Louis, so it was always a dream of his to be back here. And once I ended up here, I really have loved St. Louis as well. So this is home for us and our two babies who are ages one and two, and they are one year and one day apart exactly. Mikkael Sekeres: Oh my word. Well, you are definitely in the thick of it, aren't you? Maggie Cupit-Link: It's a very busy, chaotic life, but I'm very grateful. And so that makes it worth it. Mikkael Sekeres: That sounds fantastic. Well, I'm calling in from Miami today, so believe me, the thought of being in Rochester, Minnesota is not very appealing in mid-February. Maggie Cupit-Link: I believe that. I'm glad I'm not there right now. Mikkael Sekeres: Gee, I didn't know about your history of having cancer yourself. What was it like to return for fellowship at the place where you yourself were treated? Maggie Cupit-Link: That was an incredible experience for me. It was very emotional as well. I remember the first day of fellowship getting a tour and crying throughout the tour. More tears of joy, but it was, it was really surreal. It was really special. And I got to learn from some of the doctors who treated me, which made it really special as well. I'm really glad I got to train there and to be at a place with such a large volume of pediatric oncology patients was a really great learning experience. Mikkael Sekeres: I wonder, infrastructures, buildings change over a few years, particularly in medical centers. Was there ever a moment when you were talking to a patient who was sitting in the same chair where you were sitting when you were a patient? And was that something that you were open to sharing with people? Maggie Cupit-Link: All the time, on all accounts. Yes. The infrastructure has changed. It continues to grow significantly, but the clinic hadn't changed at that time. I think it will in the next couple of years. But the solid tumor clinic where I was treated was exactly the same. And there were many times where I took care of sarcoma patients and Ewing sarcoma patients who were teenagers as I had been in the very same rooms and times where I learned from my own oncologist as he was teaching me and training me. So it made it really special. It made empathy a big part of my experience. And I think it is for all of our experiences in oncology in particular, but I think that empathy has always been a huge part of my job and something that comes to me naturally, which is a gift. But as is sort of alluded to in my piece that we're discussing today, can be difficult at times. Empathy can also sometimes be a curse when it's hard to turn off, and that's been something as a mother now that I've really had to learn to cope with is like figuring out when my empathy might not serve me in moments and might not serve the patient in moments, and when it is an asset and a gift. Mikkael Sekeres: Empathy at the deepest possible level, having walked the same path your patients have walked as well. Really a remarkable story, Maggie. Maggie Cupit-Link: I'm very blessed to get to be alive and well, but especially to get to have a job that's so meaningful to me and hopefully can share my experience in a way that helps my patients. Mikkael Sekeres: And you share it through writing as well. When did you start writing narrative pieces? Maggie Cupit-Link: I started writing a lot when I was a cancer patient for more like a journal experience. And I had a CaringBridge page, which is one of these social media pages where families update their friends a lot on what's going on. And I started journaling daily, and then ended up publishing a book of my experience as a patient. I had also done a lot of writing of letters to my grandfather who's a retired professor of Christian philosophy because during my illness, I was really struggling with my faith and having a lot of questions as we all do when encountering children with cancer, "Why? Why God?" And so the book is actually called Why God? Suffering Through Cancer Into Faith, and it's a collection of narratives that I exchanged with my grandfather. And his part is more philosophical, and mine is more raw and emotional and expressive of the grief that I was feeling at the time as a patient. So that was the first big time I did narrative medicine, but I've found myself continuing to do so as a way to cope and process things that I go through. And the most recent one before the one we're discussing today was a piece about fertility that was published in JCO Cancer Stories and also I got to do the podcast for that piece. And that was about my experience losing fertility as a patient and how that has impacted what I tell patients about fertility and how I counsel them about possible fertility loss. And the plot twist there is that I actually have two miracle babies that I birthed for some reason after 13 years of menopause. So now I'm not infertile, but I'm very passionate about fertility as well. Mikkael Sekeres: Well, I remember that essay. I also remember how impactful that was to a lot of people who read it and how helpful it was. And gave a lot of people hope. Maggie Cupit-Link: I think hope is very, very important and necessary in the realm of cancer. Mikkael Sekeres: My word, you have so much that you could potentially share with your patients on their journey. Have you also been open to sharing your faith with them? Maggie Cupit-Link: Absolutely. I am. I think that it's something I'm really cautious not to push on anyone, but whenever patients bring up faith and want to talk about that or when they introduce that as a topic and make it clear that that's something that they are thinking about, then I'm definitely very open about that too. Mikkael Sekeres: Well, that must be a comfort to them. Maggie Cupit-Link: I hope so. It's a comfort to me as well. For me, I don't know how I would do this job and lose patients and children to death if I didn't believe in something more. Mikkael Sekeres: It's beautifully said. In this essay, you make a close connection to your patient and his mother when you write, "I imagined my own son contained in a hospital room, attached to an IV pole, vomiting from chemotherapy. I could feel the warmth of his skin against mine and the weight of his body on my chest. And as I looked back at Tristan's mother, I could only support her decision to hold her baby." What is the importance of this connection to patients, and are there any downsides? In other words, you know, in medical school, we're often taught to keep a distance, or there was an essay I wrote with Tim Gilligan, who's a GU oncologist and this incredible communicator, where we wonder if all the communication classes we're exposed to in medical school actually undo our natural communication and our natural connection because we figure, "Gee, if we have to take all these classes on communication, maybe we've got to communicate differently." What is the importance of this connection to patients, and are there any downsides? Like, should we keep a distance or not? Maggie Cupit-Link: I don't know if we should, but I know that I can't. This is my gift and my curse. I think that taking care of someone with a sick baby, especially as a parent, is so human and so full of emotion that it's not possible for me not to feel that connection. Now, I do think there's a point at which I have to be careful that what I'm doing and what I'm expressing doesn't make it harder for them. I think it's important for them to know that I feel for them and that I am having these feelings, but I don't want it to become about me when I'm trying to help them. So I once in one of these medical school situations was told that the moment the family begins to comfort me might be a moment that I've known I've gone too far. And so I think that's a rule of thumb I think about is like, if I'm crying in this moment with this family, does that make them feel loved, or does that make them feel like they need to worry about me? And I think most of the time it just makes them feel loved, but that's sort of the tension there. I think when it comes to me too, I've been unable so far to put up boundaries to protect myself emotionally. I don't know that I'm capable of that, but more importantly, I don't think that's authentic for me. And so I don't do that. I'm trying to process and grieve so that I can cope and continue to be the doctor and person that I am. But I refuse to put up emotional walls because I don't think that will serve the patient or be authentic to who I am as a person. Mikkael Sekeres: You bring up a couple of really important notions, and the first is authenticity, being true to ourselves. And if we're not true to ourselves, our patients will see through that and wonder if we're not being true to them. And also having our antennae up to get the pulse of the room, to see how people are reacting to what we're doing and making sure that we're serving our patient's needs more than we're serving our own needs when we're actually in the clinic room with our patients. Maggie Cupit-Link: Definitely, I agree. And and those scenarios in medical school, I remember just thinking to myself that it didn't make a lot of sense to me and that I was lucky that this class wasn't meant for me, that I'll just do what I feel is appropriate. And I always did really well in the simulations, but I had no way to articulate why I knew what to do. It just, for me, I was so lucky that part came naturally, and I think it does in many of us who find medicine as a calling. But I don't know how to teach or learn that. Mikkael Sekeres: Well, you've seen it from the other side as well. I mean, you strike me as being a naturally empathic person and someone who's tuned into other people's emotions. But you've also been there. You're more tuned in than I am, having been someone who's had cancer. I've certainly had close family members who've had cancer, my mom has lung cancer, for example. So I've been in the role of somebody in the room who's supporting somebody with cancer, but I haven't myself had cancer the way you have. Maggie Cupit-Link: It definitely impacts my empathy. And I think that I was surprised after becoming a mother how much that also changed things for me and impacted my empathy further. Until you're a parent, you really don't know the depth and intensity of your love for a child or a person. And it was only then that I realized how heartbreaking it might be to lose a child. It's very difficult to suppress that empathy. And that's when it might not be helpful sometimes is when I'm leaving work and thinking about someone who lost their baby and knowing that no matter how much I empathize with them, it's not going to fix it. It's been the first time in my career and maybe my life where I've had to tell myself that maybe it's okay not to have empathy in this moment. Like, maybe I should turn it off for a little bit so that I can relax and enjoy my baby. Mikkael Sekeres: My God, it's such an interesting perspective. I think as oncologists, we have this different perspective on illness and, and if we're smart about it, if we're really focused and in the moment, we appreciate the aspects of life and realize how precious they can be. And that can be a lovely thing and something we pass on to our kids. I will tell you, my own children have accused me of brushing off some of their maladies with the refrain, "Well, it may hurt you, but it's not leukemia." Maggie Cupit-Link: I've heard that's common with physician's children, but it takes a lot to get a rise out of the parent. Mikkael Sekeres: You write at one point in the essay, "At first, I believed that I had no right to grieve in this way, that it was his mother's grief, Tristan's mother, not mine. I reminded myself that I was not Tristan's mother. I did not give birth to him or name him." Now, we recently published an essay about grieving called "Are You Bereaved?" by Trisha Paul, where she also wonders whether we as oncologists have a right to grieve. What do you think? Do we? Maggie Cupit-Link: I have to note that Trisha and I were co-fellows together in our training, so I'm happy that you mentioned her. And I need to go read that essay. I haven't read that one, so I will. It's weird to wonder if we have the right to grieve. My grandmother is a psychologist, and I remember as a child saying like, "I know I shouldn't feel this way, but" about some random thing. And I remember her saying, "Feelings aren't 'should'. Feelings just 'are'." So like, maybe it doesn't matter if we should or shouldn't, but if we are grieving, we're grieving. I think in some ways it feels like I don't have the right to grieve because I have this wonderful, happy life. And this can be true of survivorship as well when I'm taking care of many children who won't get to be survivors, especially because I care for a lot of sarcoma patients. But I often wonder like, "Am I allowed to be this happy," or "am I allowed to not be happy because there's so much grief in their lives?" So it's hard. I feel this tension often like, I'm not allowed to grieve as much as this mom, but also I better be really, really happy because I'm okay and my baby's okay. It's hard when we compare our emotions to other people's who are going through different things. But it, but it's hard not to wonder, like, "Am I allowed to feel this way?" "Am I supposed to feel this way?" For me, that's when writing is helpful. Just writing down what I feel in great detail helps me move through the feelings, I guess. Mikkael Sekeres: Part of the processing of it. You described the code call for your patient vividly. You know, you draw us as readers into your essay and into that moment. We've all been in that moment. I remember when I was just talking to somebody about when I was in the intensive care unit, when I was a resident, and how at that time, a psychiatrist actually met with us every week to help us process what we were seeing in the intensive care unit, which was really remarkably forward thinking for how long ago I trained. Maggie Cupit-Link: That's really great. Mikkael Sekeres: How did you process it in real time and afterwards though? Maggie Cupit-Link: That day, even now, an aspect of me was dreading this conversation because I feel nauseated when I think back to that day, to that code, and I feel like I'm going to cry. And I don't feel like that in every code, but I think it was because of the parallels between the little boy and my baby. To note, my baby, Houston, he is a big, bald, fat faced baby with a binky in his mouth at all times, and Tristan was a fat, bald baby with a binky in his mouth at all times. And so even though there was a bit of an age difference, when I saw Tristan, I just thought of Houston, and I couldn't separate that. I feel often when I'm doing a lumbar puncture or running a code in real time on a patient, I can sort of dehumanize to the degree that's helpful where I just do what needs to be done and put aside the ick feelings. But with that child, in that code, I couldn't. And luckily I didn't have to do anything but stand there and tell them when to stop or just be supportive, but I felt sick. I felt like I couldn't do anything to help. I didn't feel like a doctor in that moment. I felt like a family member of that child. And that was really difficult. I was so lucky, and I don't know how much the piece reflects this, but the other doctor who was there, the other oncologist, is a mentor of mine who's older than me and wiser than me and very experienced. And I call her my 'work mom' lovingly. She was there, and she stepped in and helped me and checked on me and made me feel like I could handle things. It would have been much worse without her there. Mikkael Sekeres: We're fortunate when we do have our friends and colleagues to help process this because if you're not in this field, at that moment it's hard to understand just how deeply we can also feel the pain that our patients are going through. Maggie Cupit-Link: Absolutely. Mikkael Sekeres: And I do hope you'll retain that description of Houston for when you give the speech at his wedding because I'm sure he'd appreciate that. Maggie Cupit-Link: The big fat bald binky baby. Yes. Houston is now in his 'mama phase' where if I'm not holding him at all times, he fake cries, "Mama," until I do pick him up. So it's been exhausting physically, but I must pick him up. Mikkael Sekeres: I have to say it has been such a pleasure having you, Maggie Cupit-Link, join us to discuss your essay, "Mother's Grief." Thank you so much for submitting your article and for joining us today. Maggie Cupit-Link: Thank you so much for having me, and thank you for everyone for reading. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO's Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show Notes: Like, share and subscribe so you never miss an episode and leave a rating or review.   Guest Bio: Dr Margaret Cupit-Link is an assistant professor of pediatric hematology/oncology at Cardinal Glennon Children's Hospital of St. Louis University.   Additional Reading:  It Mattered Later Why, God?: Suffering Through Cancer into Faith, by Margaret Carlisle Cupit, et al

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC. Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU

Today, in honor of Black History Month, we're exploring what happens when inequity itself becomes a risk factor for breast cancer in the Black community — shaping who gets screened, how quickly they're diagnosed and, ultimately, who survives. Our guest, Dr. Lori Pierce, is a renowned radiation oncologist, former ASCO president and Komen Scholar, and national leader in advancing equity in cancer care. She has dedicated her career to improving outcomes of women with breast cancer, with a focus on the underserved, by transforming not just treatments but the systems that deliver them. Her perspective is rigorous, compassionate and urgently needed.

Can D1 competitive mindset help you dominate the medical sales industry?In this episode of the Medical Sales U Podcast, I sit down with Justin Kershaw—former Michigan State player turned top-tier Spine Endoscopy Rep for Arthrex. Justin pulls back the curtain on how he transitioned from the locker room to the Operating Room, the reality of working for a $5B company like Arthrex, and why being a "Girl Dad" and a man of faith is what actually fuels his professional drive.In this episode, you'll learn: * The "3 Gatekeepers" you must win over to close deals in any hospital.* Why Arthrex uses an "Agency" model vs. traditional distributorships. * How to maintain high-level physical and spiritual discipline in a high-stress career. * Tactical advice for career pivots (how Dave broke into sales at age 35!).

Read the full article on Oncology Data Advisor: https://oncdata.com/oncology-unfiltered-financial-toxicity In this episode of Oncology Unfiltered, Melissa Cutrona, Co-Founder and General Manager of i3 Health and Oncology Data Advisor, and Matthew Hadfield, DO, Oncology Data Advisor Editor in Chief, explore how financial and geographic toxicities in oncology are, in reality, clinical toxicities. If a patient can't afford to fill the prescription, is it really a treatment option? They discuss what financial toxicity truly means—far beyond drug prices—covering travel, parking, time off work, and the hidden costs of tests and therapies. Dr. Hadfield shares real-world examples of patients turning down innovative treatments and clinical trials because they can't afford the logistical burden, and explains how geography and income create a two-tiered system of cancer care. The conversation examines how financial and geographic barriers distort shared decision making, limit participation in clinical trials, and skew our understanding of real-world efficacy. They also highlight the role of institutions, policymakers, and pharma in improving access, and why oncologists must reconsider ordering patterns, testing habits, and how they counsel patients about the full “cost” of care. Thank you for watching Oncology Unfiltered. Check out our playlist and stay tuned for next month's topic, “Molecular Testing Chaos: Are We Over-Testing, Under-Testing, or Testing the Wrong Things at the Wrong Time?”

Sarah Poland, MD, lead author of a recently published article in the journal ONCOLOGY titled Advances in Immunotherapy for Breast Cancer, highlighted key findings from her review in a conversation with CancerNetwork®.1 Throughout the discussion, she spoke about: Shifting Perspectives on Immunogenicity: Historically, breast cancer was considered a “cold,” poorly immunogenic tumor due to low tumor mutational burden (TMB) and few tumor-infiltrating lymphocytes (TILs). Poland highlighted how clinical research has shifted this perspective, particularly through the study of triple-negative breast cancer (TNBC), which often exhibits higher PD-L1 expression and immune infiltration.Key Clinical Milestones: The review highlighted foundational data that established immunotherapy as a standard of care: Early-Stage TNBC: The phase 3 KEYNOTE-522 trial (NCT03036488) established pembrolizumab (Keytruda) plus chemotherapy as a standard neoadjuvant treatment for stage II to III TNBC.2 Metastatic TNBC: The phase 3 KEYNOTE-355 trial (NCT02819518) demonstrated the benefit of pembrolizumab in PD-L1–positive metastatic disease.3 Managing Toxicity and Rechallenge: Poland addressed the feasibility of pembrolizumab rechallenge after an immune-related adverse effect (irAE), emphasizing that while possible, it requires a highly individualized approach based on the severity and timing of the initial toxicity.The Future Landscape: Beyond PD-1/PD-L1 inhibitors, the discussion covered emerging technologies that are poised to redefine treatment: Antibody-Drug Conjugates (ADCs): Exploration of novel combinations of ADCs with immunotherapy. Emerging Modalities: The potential role of bispecific antibodies and vaccine trials utilizing tumor antigens. Subtype Expansion: Emerging evidence supporting the efficacy of immunotherapy in hormone receptor–positive and HER2-positive subtypes, moving beyond the traditional focus on TNBC. Unmet Educational Needs: Poland emphasized the importance of resources that connect providers and patients, particularly in translating complex trial data into clinical practice and addressing patient concerns regarding the newest therapies and trials.Poland is from the Department of Medicine in the Section of Hematology/Oncology at The University of Chicago.References1.        Poland S, de Oliveira Andrade M, Nanda R. Advances in immunotherapy for breast cancer. Oncology (Williston Park). 2026;40(1):8-15. doi:10.46883/2026.259210612.        Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810-821. doi:10.1056/NEJMoa19105493.        Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217-226. doi:10.1056/NEJMoa2202809

Mesothelioma can strike at any time, but it most commonly affects those in their 70s, with cases continuing well into the 2030s. The time from exposure to diagnosis can be up to 60 years. This week, we explore treatment options for pleural mesothelioma, including ipilimumab and nivolumab, and consider whether chemotherapy and bevacizumab work for mesothelioma as well. The MAPS trial was published in 2016, while Checkmate was published in 2022.Studies discussed in this episode:MAPSCheckmate 743For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Klash With Kenzie takes a dark turn. Chicago’s best morning radio show now has a podcast! Don’t forget to rate, review, and subscribe wherever you listen to podcasts and remember that the conversation always lives on the Q101 Facebook page. Brian & Kenzie are live every morning from 6a-10a on Q101. Subscribe to our channel HERE: https://www.youtube.com/@Q101 Like Q101 on Facebook HERE: https://www.facebook.com/q101chicago Follow Q101 on Twitter HERE: https://twitter.com/Q101Chicago Follow Q101 on Instagram HERE: https://www.instagram.com/q101chicago/?hl=en Follow Q101 on TikTok HERE: https://www.tiktok.com/@q101chicago?lang=enSee omnystudio.com/listener for privacy information.

Host: Mindy McCulley, MS, Extension Specialist for Instructional Support, Family and Consumer Sciences Extension, University of Kentucky  Guests: Nathan Vanderford, PhD Director, Appalachian Career Training in Oncology Program, Markey Cancer Center, Kameron Jackson and Matthew Sanders, ACTION Program student participants Cancer Conversations Episode 72 Welcome to Cancer Conversations on Talking FACS with host Mindy McCulley. In this episode we hear from Dr. Nathan Vanderford, director of the NIH-funded ACTION (Appalachian Career Training in Oncology) program, and students Kameron Jackson and Matthew Sanders about how the program engages Eastern Kentucky high school and undergraduate students in cancer education, lab research, clinical shadowing, mentorship, and community outreach. Topics covered include student experiences in research labs and mentorship, the program's recruitment across the 54 Appalachian counties, and a unique writing project that produced four books of personal and realistic fictional stories about cancer in Eastern Kentucky. Kameron and Matthew describe how writing helped them process family history, spark conversations about cancer, and build communication skills alongside scientific training. Key takeaways: ACTION provides hands‑on research and outreach opportunities that change career trajectories, creative writing can open difficult conversations about cancer in communities, and the program aims to broaden access across the region. Find the students' stories and the full book linked in the episode show notes and visit Markey.uky.edu or the UK Markey Cancer Center Facebook page for more information. Click the images below to hear student read excerpts from Cancer in Appalachia: A Collection of Youth Told Stories   For more information about : Appalachian Career Training in Oncology Program ACTION Books Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey

Season 10, Episode 1 of the PQI Podcast kicks off with a global perspective on cancer care, featuring Eoin Tabb, a leading oncology and haematology pharmacist in Ireland. Eoin serves as Chief 2 Pharmacist for Clinical Cancer Services at University Hospital Waterford, hosts the Irish Haematology Oncology Podcast, and is the Chairperson of the Irish Pharmacy Haematology Oncology Society. In this episode, he shares insights into: • How oncology and haematology pharmacy practice is structured in Ireland • The role of pharmacists within multidisciplinary cancer care teams • How digital health and artificial intelligence are being applied in real-world oncology settings • Opportunities for shared learning and collaboration across oncology systems

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Robert Kantor, MD. Dr Kantor is associate medical director of Medical Oncology & Hematology at Private Health Management.Drs Camidge and Kantor reflected on Dr Kantor's decades-long career. Inspired by his father's devotion to patients, Dr Kantor fast-tracked his education, entering medical school at Wayne State University without completing an undergraduate degree. Following fellowship, he intentionally chose private practice over academic oncology to focus on direct patient care and making a difference in the lives of patients' families.Dr Kantor's career illustrates the shifting landscape of American medicine. He has navigated various oncology practice models, including a corporate merger that he felt compromised patient care. In 2008, he took the risk of launching his own solo practice, successfully bringing trusted staff and a dedicated patient base with him.Dr Kantor eventually retired from clinical practice due to burnout, which was exacerbated by corporate management challenges and the inefficiencies of electronic medical records. His retirement evolved into an "encore career" as an associate medical director for Private Health Management. In this consultative role, he provides clinical oversight for complex oncology cases, helping patients navigate toward personalized cancer vaccines, clinical trials, and cutting-edge therapies. Dr Kantor expressed that this work has brought him renewed enthusiasm for the field of oncology, as it allows him to use his decades of experience with a basis of a better work-life balance. He remains passionate about how these high-end, personalized technologies will eventually make their way into routine clinical practice to benefit the broader patient population.

Have you longed to integrate your Christian faith into your patient care—on the mission field abroad, in your work in the US, and during your training? Are you not sure how to do this in a caring, ethical, sensitive, and relevant manner? This “working” session will explore the ethical basis for spiritual care and provide you with professional, timely, and proven practical methods to care for the whole person in the clinical setting. https://www.dropbox.com/scl/fi/qpah9kh1lttg6cm1jjop9/Bob-Mason-Ethics-of-Spiritual-Care-revised.pptx?rlkey=0emve2ja8282nv8xc4uinq1hg&st=9033htwx&dl=0

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Antonia and Andrew discuss the February 18, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Knee, Oncology, Pediatrics, Shoulder, Hand & Wrist, Orthopaedic Essentials, Trauma, Spine Chapters (00:00:03) - Case is On Hold(00:00:45) - Episode 100(00:03:03) - Sneak Preview: Miller Review Course(00:03:42) - AI Generated Text in Orthopedics(00:05:36) - AI in Orthopedics: The Promised Land(00:13:44) - Artificial Intelligence in orthopedic and sports medicine(00:16:27) - Osteo and Sports Medicine Editorial Policies on AI(00:24:42) - How to Write a Paper With a Computer(00:25:16) - Deep Learning Model for Differentiating Neoplastic Fractures from Non(00:31:36) - The Ms. Cleo Phone Paradigm(00:32:34) - Machine Learning and Neoplastic Fractures(00:37:05) - AI-driven CT MRI Image Fusion and Automatic ACL Reconstruction(00:39:05) - A 100 Episodes of JBGS: Thank You!(00:40:46) - Aisha Abdeen Is The Next Co-Host!

Send a textAt this point in exam prep, many oncology physical therapists find themselves asking, “Is it too late?” And this LOADED question often comes with fear, pressure, and self-doubt.In this episode, we talk through how to think about this question honestly and calmly, how fear distorts decision-making, and why discernment is a critical professional skill.We cover:• Why this question shows up late in exam prep• The difference between panic-based and clarity-based decisions• Why pausing is not the same as quitting• How honest decisions protect long-term confidenceLooking for more structure and clarity?You can find a visual walkthrough of this decision point in the YouTube playlist here:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7 Looking for more structure and clarity?If you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure what to focus on, I've created a short YouTube playlist designed to help you study with more clarity and confidence.These videos walk through prioritization, common pitfalls, and how to think about exam prep more strategically — without Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen Liu Guests: Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology. Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

Today's conversation is a deeply personal look at what it means to be diagnosed with breast cancer at just 30 years old. We often hear the statistics that more young women are being diagnosed, but numbers can't capture the shock of finding a lump before you think you're even old enough to worry… or the life-altering shift that happens when you are put into medically induced menopause. Caroline McNally knows the struggles of being in the thick of treatment and the isolation of being diagnosed younger than most. But she also knows about strength, hope and learning how to advocate for herself and others.

Is it time to trade your scrubs for a corporate career? In this episode, we sit down with Sydney Gramuglia, a Registered Nurse who successfully transitioned from bedside burnout to a high-impact, 6-figure role as an Oncology Clinical Educator at Eversana partnering with Sun Pharma. Sydney didn't have prior sales experience, and the job she landed wasn't even listed in her state—but she beat out veteran candidates anyway. Today, we're pulling back the curtain on the "Medical Sales U" blueprint she used to master a grueling 5-round interview process and land her dream job in the pharmaceutical industry.INSIDE THIS EPISODE:*The "Experience" Myth: Why "not enough experience" is usually a cover for "not enough preparation."*The LinkedIn Transformation: How Sydney went from 20 connections to 500+ and got headhunted by hiring managers.*The Mock Presentation: The exact 40-step rehearsal strategy Sydney used to master complex MOA (Mechanism of Action) and PD-L1 pathways.*Clinical Educator vs. Sales: Understanding the different paths for nurses in pharma.*The Contract Partnership: How the Eversana and Sun Pharma collaboration works.CHAPTERS:0:00 – Meet Sydney: From Bedside Nurse to Pharma Pro2:15 – The "Depressing" Reality of Nursing during COVID5:00 – Finding a Passion for Oncology7:30 – Why Your LinkedIn Profile Is Your New Resume9:15 – Breaking Down the Sun Pharma Offer13:45 – Clinical Educator vs. Sales: Which is right for you?16:10 – The Brutal Rejection that changed everything23:50 – Preparing for the 5-Round Interview Gauntlet25:30 – How to Ace a Mock Clinical Presentation31:00 – The Power of the Medical Sales U Community36:45 – Lifestyle Design: The perks of a corporate clinical role39:30 – Exploring Charleston: Best food & dog-friendly spotsCONNECT WITH Sydney Gramuglia - https://www.linkedin.com/in/sydney-gramuglia/READY TO BREAK INTO MEDICAL SALES? We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #NurseCareerChange #PharmaJobs #ClinicalNurseEducator #MedicalSalesU #NursingBurnout #CareerPivot #SunPharma #Eversana #MedicalDeviceSales #HealthcareInnovation

Brachytherapy is an inside-out radiation approach to treating tumors that may offer advantages over external beam radiation in some situations. Samuel Marcrom, M.D., a radiation oncologist, discusses how brachytherapy differs from external beam radiation including its situational advantages and challenges, as well as common uses. He explains patient selection, treatment logistics, and the UAB patient experience.

We heard stories of physicians practicing in the USA in a specialty different from the ones they originally trained in, perhaps even from a different country. In this episode, Dr. Czarnkowski shared with us about his journey of how he first got interested in medicine, then gynecological oncology, and finally to psychiatry as well as his insights and hopes for the field of psychiatry. Trigger Warning: suicideDr. Czarnkowski (Tscharnkoffsky), is an Affiliate Associate Professor of Psychiatry at Loyola University Chicago Stritch School of Medicine and an Attending Psychiatrist at the Edward Hines Jr. VA Hospital, where he also serves as Director of Emergency Psychiatry Services and provides care in the Acute Recovery Clinic and outpatient mental health. He previously held faculty and consultation-liaison roles at the University of Illinois at Chicago and served at Advocate Christ Medical Center, including leadership of CL and Acute Inpatient Psychiatry services.Dr. Czarnkowski earned his medical degree from Jagiellonian University Medical College in Krakow, completed postgraduate training in gynecological oncology in Poland and the UK, and completed psychiatry residency at the University of Illinois at Chicago. He is board certified in General Psychiatry and Consultation-Liaison Psychiatry. He's clinician-educator, he teaches key residency curricula, supervises trainees and medical students across emergency and outpatient settings, and has received multiple institutional awards for teaching excellence including Dept. of Psychiatry Chairman's Award for Dedication in Teaching and Resident's Education and was a three time recipient of Wolf and Kettle Award.Episode produced by: Deborah ChenEpisode recording date: 12/02/2025www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。

How do breakthroughs in the lab become real-world treatments that save lives? In this episode, Professor Stephen Maher of Trinity College Dublin joins us to discuss the rapidly evolving field of translational oncology and how cutting-edge research is shaping the future of cancer therapy. As a leading expert in radiation research and Director of Postgraduate Studies for the School of Medicine at Trinity, Stephen focuses on a critical question: why do some cancers respond to treatment while others resist it? His work examines the role of microRNAs, tumor hypoxia, and DNA damage response in shaping how cancers react to chemotherapy and radiotherapy — with particular attention to oesophageal and pancreatic cancers. In this episode, we explore: ·       Where anti-cancer therapeutics are headed in the coming years ·       How radiation research is evolving to improve treatment precision ·       Why translational oncology is essential for turning discovery into patient care ·       How treatment resistance forms — and what researchers are doing to overcome it After earning his Ph.D. in Oncology at RCSI and completing a fellowship at the National Cancer Institute in Maryland, Professor Maher has dedicated his career to bridging the gap between scientific discovery and clinical impact. He leads major national and international collaborations and has helped build advanced radiotherapy and hypoxia research programs at Trinity's Translational Medicine Institute. Learn more about Professor Maher and his work here. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Treatment is a significant part of overcoming breast cancer, but what about the mental, physical and emotional challenges this disease presents? Sarah Cipolla and Tawana Davis both relied on their faith to get through breast cancer. Through it all – the ups and downs and good times and setbacks – they had hope for better days and trusted in their faith. Hope and faith are powerful forces during challenging times. Susan G. Komen leads Worship in Pink, a nationwide program that brings breast health education to faith communities. Through this effort, Komen can reach people who don't participate in breast health care and people who rely on their faith to overcome life's challenges. Thanks to Merck and Novartis for supporting the Worship in Pink Program